NOVARTIS AG

NOVN
Delayed Quote. Delayed  - 04/15 11:31:49 am
80.53CHF +0.81%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 48 65952 070
EBITDA1 16 84518 506
Operating profit (EBIT)1 15 41616 499
Operating Margin 31,7%31,7%
Pre-Tax Profit (EBT)1 9 87812 167
Net income1 8 07210 051
Net margin 16,6%19,3%
EPS2 3,554,64
Dividend per Share2 3,383,29
Last update 01/26/202104/15/2021
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 24 50022 927
Net Cash position1 --
Leverage (Debt / EBITDA) 1,45x1,24x
Free Cash Flow1 11 69114 080
ROE (Net Profit / Equities) 23,5%25,1%
Shareholders' equity1 34 37640 027
ROA (Net Profit / Asset) 6,45%8,19%
Assets1 125 215122 728
Book Value Per Share2 25,125,9
Cash Flow per Share2 5,956,77
Capex1 1 2751 620
Capex / Sales 2,62%3,11%
Last update 01/26/202104/15/2021
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 197 026 M $ -
Entreprise Value (EV) 219 953 M $ 214 216 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) 18,8x 17,4x
Capitalization / Revenue 3,78x 3,63x
EV / Revenue 4,22x 4,05x
EV / EBITDA 11,9x 11,2x
Yield (DPS / Price) 3,77% 3,90%
Price to book (Price / BVPS) 3,37x 3,19x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 31,7% 33,1%
Operating Leverage (Delta EBIT / Delta Sales) 1,00x 2,09x
Net Margin (Net Profit / Revenue) 19,3% 20,4%
ROA (Net Profit / Asset) 8,19% 8,75%
ROE (Net Profit / Equities) 25,1% 26,9%
Rate of Dividend 70,9% 67,9%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   3,11% 3,09%
Cash Flow / Sales 29,4% 30,4%
Capital Intensity (Assets / Sales) 2,36x 2,33x
Financial Leverage (Net Debt / EBITDA) 1,24x 0,88x
Price Earning Ratio
EPS & Dividend